Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Lexicon pharmaceuticals, inc. crawled date : 2022 - 05 - 12 save search
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes
Published: 2021-12-30 (Crawled : 06:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 2.5K
|
Health Technology
|
| O: 6.95%
H: 5.81%
C: -11.66%
treatment drug heart application diabetes
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
Published: 2022-03-17 (Crawled : 06:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 2.5K
|
Health Technology
|
| O: 0.91%
H: 3.6%
C: -1.35%
commercialization
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
Published: 2022-03-21 (Crawled : 06:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 2.5K
|
Health Technology
|
| O: 0.46%
H: 2.5%
C: -1.36%
trial cardiovascular
Lexicon Welcomes New Guidelines for the Management of Heart Failure
Published: 2022-04-04 (Crawled : 06:00) - globenewswire.com
LXRX | $1.6 -0.62% -0.63% 2.5K
|
Health Technology
|
| O: 1.78%
H: 13.1%
C: 10.04%
guidelines management heart
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
TRU | $74.475 8.44% 100K
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.